Apis Cerana Whole Beef Liver Bombyx Mori Whole Bor
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Apis Cerana Whole Beef Liver Bombyx Mori Whole Bor
- Multi-Allergen Complex (Apis Cerana / Corticotropin / Histamine / et al.): Insufficient Data for Repurposing Analysis
Multi-Allergen Complex (Apis Cerana / Corticotropin / Histamine / et al.): Insufficient Data for Repurposing Analysis
One-Sentence Summary
This candidate consists of a 15-component biological mixture including insect whole-body extracts, animal-derived materials, a microbial antigen (Borrelia burgdorferi), and pharmacological agents (Corticotropin, Histamine dihydrochloride), resembling a multi-allergen immunotherapy or desensitization preparation. No approved indication was found in the Taiwan (TFDA) database, and TxGNN returned no predicted new indications for this candidate. As a result, a standard repurposing evidence evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indications on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and none exists) |
| US Market Status | Not marketed (no TFDA licenses found) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction is available for this candidate, so a mechanistic justification for repurposing cannot be constructed at this time.
The drug INN string describes a heterogeneous mixture of 15 substances spanning insect whole-body antigens (Asian honeybee, silkworm, dog flea, common mosquito, house fly, Australian cockroach, paper wasp, fire ant, deer fly, black widow spider), animal organ extracts (beef liver, pig adrenal gland), a spirochete antigen (Borrelia burgdorferi), a peptide hormone (Corticotropin/ACTH), and a biogenic amine (Histamine dihydrochloride). This composition is consistent with a multi-allergen desensitization or provocation-testing preparation rather than a conventional small-molecule drug.
Because each component carries its own pharmacological profile and the mixture lacks a unified DrugBank entry, the TxGNN knowledge-graph cannot map it to a single drug node. This structural incompatibility — not a gap in clinical evidence — is the primary reason no predictions were generated. Resolving this requires decomposing the mixture into individual active substances and running predictions on each component separately.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No TFDA authorizations on record for this drug string.
Safety Considerations
Please refer to the package insert for safety information.
Note: All safety fields (key warnings, contraindications, drug–drug interactions) returned no data for this query. Given that the mixture contains potent biological materials — including a venomous arthropod extract (Latrodectus mactans / black widow spider), a live-organism antigen (Borrelia burgdorferi), and a vasoactive amine (Histamine dihydrochloride) — clinical use without verified safety documentation is inadvisable.
Conclusion and Next Steps
Decision: Hold
Rationale: TxGNN produced zero predicted indications, and the drug has no regulatory history in Taiwan, leaving no evidence base — clinical, regulatory, or model-derived — on which to build a repurposing case.
To proceed, the following is needed:
- Decompose the mixture: Split the 15-component INN into individual substances and resubmit each to the TxGNN pipeline separately (priority candidates: Corticotropin, Histamine dihydrochloride, Solenopsis invicta extract).
- Identify the intended product class: Confirm whether this is an allergen immunotherapy product, a homeopathic preparation, or a diagnostic reagent kit, as each class follows a different regulatory and evidence pathway.
- Retrieve DrugBank IDs for mappable components (Corticotropin: DB00716; Histamine: DB04660) to enable KG-based prediction on individual agents.
- Retrieve original indication / package insert: Search FDA NDC/NDA databases and TFDA for products containing this combination to establish the intended therapeutic context.
- Safety documentation: Obtain the full package insert or SDS for each biological component before any further analysis, given the presence of venom-derived and infectious-agent-derived materials.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.